B. De Valk - Concepedia

Author

B. De Valk

The Netherlands Cancer Institute

Also Known As

B de Valk, B. De Valk, B. de Valk, Bas Valk

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

The Netherlands Cancer Institute OLVG Amphia Ziekenhuis Hospital Universitario 12 De Octubre Radboud University Medical Center

About

B. De Valk is an author at The Netherlands Cancer Institute specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	1.9K
2	Pathology	3	3	140
3	Surgical Oncology	2	2	1.8K
4	Hepatology	1	1	10
5	Obstetrics	1	1	290

B. De Valk

Publications

Citations

H-Index

Page 1

	Year	Citations
Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial Renu R. Bahadoer, Esmée A. Dijkstra, Boudewijn van Etten, The Lancet Oncology Surgical OncologyRadiation TherapyGastrointestinal OncologyMedicineColorectal Cancer	2020	1.5K
Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials Ignace Vergote, Corneel Coens, Matthew Nankivell, The Lancet Oncology Surgical OncologyGynecological SurgeryIndividual Patient DataMedicineChorus Trials	2018	290
First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients Ian E. Smith, Jean‐Yves Pierga, Laura Biganzoli, Annals of Oncology Metastatic Breast CancerBreast OncologyFirst-line BevacizumabMedicinePathology	2010	103
Biochemical expression of heterozygous hereditary hemochromatosis B. De Valk, Ruben S. G. M. Witlox, Yvonne T. van der Schouw, European Journal of Internal Medicine Biochemical ExpressionGeneticsPathologyHeme SignalingHeme Homeostasis	2000	27
Alveolar soft-part sarcoma responding to interferon alpha-2b K. J. Roozendaal, B. De Valk, J J A ten Velden, British Journal of Cancer	2003	23
LBA27 First-line systemic treatment in patients with initially unresectable colorectal cancer liver metastases (CRLM): Overall survival of the phase III CAIRO5 study of the Dutch Colorectal Cancer Group Cornelis J.A. Punt, Marinde J. G. Bond, Karen Bolhuis, Annals of Oncology HepatologyOverall SurvivalMedicineColorectal CancerPathology	2023	10

Page 1